NCT07817251ClinicalTrials.gov
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes
בקצרה
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…
שלב 3דרושים 210 משתתפים40 אתריםמדינה אחת
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT07817251פתיחת רשומה זו ב־ClinicalTrials.govסונכרן לפני חודשיים
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 210 participants (target), run at 40 sites.
How this score is built
- Enrolment22/40
210 participants (target)
- Site count19/25
40 sites
- Country count0/15
Single country
- Planned duration4/10
Planned over about 10 months
- Sponsor scale9/10
Novo Nordisk A/S has led 339 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
מצבים רפואיים
- Diabetes Mellitus, Type 2
זכאות
| מין | הכול |
|---|---|
| גילאים | 18 Years – ללא מקסימום |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 3 |
| הקצאה | אקראי |
| מודל ההתערבות | PARALLEL |
| מטרה ראשית | TREATMENT |
| הסתרה | QUADRUPLE (4) |
| גיוס | דרושים 210 משתתפים |
נותן חסות ושותפים
- Novo Nordisk A/S נותן חסות
זרועות והתערבויות
- CagriSema dose 1EXPERIMENTAL
Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.
- CagriSema dose 2EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.
- CagriSema dose 3EXPERIMENTAL
Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.
התערבויות
- תרופה CagriSema
CagriSema will be administered s.c. once weekly.
מדדי תוצאה
מדד תוצאה ראשוני
Number of treatment emergent adverse events (TEAEs)
Measured as count of events.
מסגרת זמן From baseline (Week 0) to end of treatment (Week 16)
מדד תוצאה משני
Number of TEAEs
Measured as count of events.
מסגרת זמן From baseline (Week 0) to end of study (Week 22)
מדד תוצאה משני
Number of TEAEs
Measured as count of events.
מסגרת זמן From baseline (Week 0) to Week 8
מדד תוצאה משני
Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)
Measured as count of episodes.
מסגרת זמן From baseline (Week 0) to end of study (Week 22)
מדד תוצאה משני
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
מסגרת זמן From baseline (Week 0) to end of study (Week 22)
מדד תוצאה משני
Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)
Measured as count of episodes.
מסגרת זמן From baseline (Week 0) to Week 8
מדד תוצאה משני
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Measured as count of episodes.
מסגרת זמן From baseline (Week 0) to Week 8
מדד תוצאה משני
Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)
Measured as count of participants.
מסגרת זמן From baseline (Week 0) to end of treatment (Week 16)
תאריכים
| תאריך התחלה | 16 בספטמבר 2026 (בפועל) |
|---|---|
| סיום ראשוני | 9 ביוני 2027 (משוער) |
| סיום | 21 ביולי 2027 (משוער) |
| פורסם לראשונה | 14 בספטמבר 2026 (בפועל) |
| עודכן לאחרונה | 30 בספטמבר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | ספטמבר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
37 אתרים מגייסים
United States
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Albuquerque Clinical Trials Inc. | Albuquerque | New Mexico | מגייס |
| Amarillo Med Spec LLP | Amarillo | Texas | מגייס |
| Texas Diabetes & Endocrinology | Austin | Texas | מגייס |
| Northern Pines Hlth Ctr, PC | Buckley | Michigan | מגייס |
| North Texas Endocrine Center | Dallas | Texas | מגייס |
| Northeast Research Institute | Fleming Island | Florida | מגייס |
| Diabetes and Thyroid Center of Fort Worth | Fort Worth | Texas | מגייס |
| Ark Clinical Research | Fountain Valley | California | מגייס |
| Gilbert Center For Family Medicine | Gilbert | Arizona | מגייס |
| Thrive Clinical Research Group | Glendora | California | מגייס |
| PharmQuest Life Sciences LLC | Greensboro | North Carolina | מגייס |
| AGA Clinical Trial | Hialeah | Florida | מגייס |
| East West Med Res Inst | Honolulu | Hawaii | מגייס |
| JCCT- Juno NW Houston | Houston | Texas | מגייס |
| Sante Clinical Research | Kerrville | Texas | מגייס |
| Scripps Whittier Diabetes Inst | La Jolla | California | מגייס |
| Palm Research Center Inc-Vegas | Las Vegas | Nevada | מגייס |
| DCOL Ctr for Clin Res | Longview | Texas | מגייס |
| Downtown LA Res Ctr. Inc. | Los Angeles | California | מגייס |
| Advanced Medical Research | Maumee | Ohio | טרם מגייס |
| Adult Medicine of Lake County, Inc | Mt. Dora | Florida | מגייס |
| Clinical Research Associates | Nashville | Tennessee | מגייס |
| Tidewater Physicians Multispecialty Group | Newport News | Virginia | מגייס |
| Alliance for Multispecialty Research | Newton | Kansas | מגייס |
| North Hills Medical Research Inc | North Richland Hills | Texas | מגייס |
| Valley Clinical Trials, Inc. | Northridge | California | מגייס |
| Optimal Research Sites | Orange City | Florida | מגייס |
| Dream Team Clinical Research | Pomona | California | מגייס |
| Clinical Trials Research_Sacramento | Sacramento | California | מגייס |
| J.Lewis Research Inc | Salt Lake City | Utah | מגייס |
| NE Clin Res of San Antonio | San Antonio | Texas | טרם מגייס |
| Linda Vista Health Care Ctr | San Diego | California | מגייס |
| Diabetes & Endo Treatment Spec | Sandy City | Utah | טרם מגייס |
| Endeavor Health | Skokie | Illinois | מגייס |
| Chrysalis Clinical Research | St. George | Utah | מגייס |
| Cotton O'Neil Diabetes & Endocrinology | Topeka | Kansas | מגייס |
| Chase Medical Research LLC | Waterbury | Connecticut | מגייס |
| Iowa Diabetes & Endo Res Ctr | West Des Moines | Iowa | מגייס |
| Metabolic Research Institute Inc | West Palm Beach | Florida | מגייס |
| Accellacare Wilmington | Wilmington | North Carolina | מגייס |
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 30 בספטמבר 2026
המצב השתנה
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 30 בספטמבר 2026
הגיוס נפתח
Recruitment opened
NOT_YET_RECRUITINGRECRUITING